Publications
July 14, 2021
International Journal of Toxicology
Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease
May 11, 2021
Advances in Therapy
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
March 22, 2021
International Journal of Toxicology
Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
Posters
July 2022
Federation of American Societies for Experimental Biology
Selective Targeting of Matrix-Associated TGFβ1 is an Attractive Approach for Anti-Fibrotic Therapy
June 2022
CURE SMA Annual Conference
Topaz Extension: 24-Month Efficacy and Safety: Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
June 2022
CURE SMA Annual Conference
Treatment Effects Among Patients with Type 2 and Type 3 SMA: Directly Reported by Patients and Caregivers from the TOPAZ Clinical Trial